Loading
Measuring how much radiation dose each organ and tumour actually received from a radioactive drug.
Dosimetry is the measurement of how much radiation dose each organ and each tumour actually received from a radioactive drug. It relies on post-therapy SPECT/CT imaging at several time points and enables personalised activity prescription instead of fixed doses, and regulators and payers increasingly require it. The term is linked to the SPECT & bone scan and Radioligand therapy (beta emitters) technologies and to Radioembolisation (TARE / SIRT, yttrium-90), Auger-electron therapy and Total-body PET for screening. It is referenced by the Hepatocellular carcinoma and Neuroendocrine tumours entries, the radiopharmaceutical roadmap and the bottleneck on wrong doses, and by ideas on dosimetry-personalised PRRT instead of four fixed cycles and total-body PET for personalised radioligand dosing.
Showing the technology this term belongs to: SPECT & bone scan.
Patients newly diagnosed with an advanced grade 2 or 3 neuroendocrine tumour of the gut or pancreas that shows somatostatin receptors on imaging can now receive lutetium dotatate as their first treatment, gaining more than a year of additional disease control and a much higher chance of tumour shrinkage. It does not settle whether radioligand therapy is better than other first-line options such as capecitabine-temozolomide or everolimus, and long-term marrow safety with earlier use needs surveillance.
Men with metastatic castration-resistant prostate cancer that has progressed after hormonal therapy and chemotherapy, and whose tumours show PSMA on a PET scan, can now receive lutetium-PSMA, which extends life, controls pain and is usually better tolerated than further chemotherapy. It has established a new treatment class in which a scan decides who gets the matching radioactive drug, and it is now being tested earlier in the disease (PSMAfore, PSMAddition).
Shares Regional cyclotron hubs for actinium-225 with an agreed actinium-227 impurity limit, Half-life, Alpha-emitter nanogenerators and daughter trapping, Auger-electron therapy.
Shares PRRT (peptide receptor radionuclide therapy), IRCCS Istituto Romagnolo per lo Studio dei Tumori 'Dino Amadori' (IRST), European Association of Nuclear Medicine, Society of Nuclear Medicine and Molecular Imaging.
Shares Dosimetry-personalised PRRT instead of four fixed cycles, PRRT (peptide receptor radionuclide therapy), IRCCS Istituto Romagnolo per lo Studio dei Tumori 'Dino Amadori' (IRST), European Association of Nuclear Medicine.
Shares Alpha-emitting PSMA therapy at first metastatic diagnosis, Total-body PET for personalised radioligand dosing, IRCCS Istituto Romagnolo per lo Studio dei Tumori 'Dino Amadori' (IRST), European Association of Nuclear Medicine.
Shares Regional cyclotron hubs for actinium-225 with an agreed actinium-227 impurity limit, Alpha-emitter nanogenerators and daughter trapping, Auger-electron therapy, Alpha-emitting PSMA therapy at first metastatic diagnosis.
Shares Auger-electron therapy, PRRT (peptide receptor radionuclide therapy), IRCCS Istituto Romagnolo per lo Studio dei Tumori 'Dino Amadori' (IRST), Inselspital, Bern University Hospital / University Cancer Center Inselspital.
Shares European Association of Nuclear Medicine, VISION: lutetium-177 PSMA-617 radioligand therapy extends survival in advanced prostate cancer, Radioligand therapy (beta emitters), Neuroendocrine tumours.
Shares Alpha-emitting PSMA therapy at first metastatic diagnosis, Total-body PET for personalised radioligand dosing, Radioligand therapy (beta emitters).